Gradient Denervation Technologies Announces FDA Breakthrough Designation for Pulmonary Artery Denervation System
PARIS, May 19, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today the company's pulmonary denervation system has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This program creates an expedited review pathway for devices that have the potential to provide more effective treatment for life-threatening or debilitating conditions and meet FDA's rigorous standards for safety and efficacy.
The Gradient Denervation System is a novel technology intended to treat patients with pulmonary hypertension and associated heart failure. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures.
The PreVail-PH2 Early Feasibility Study is enrolling patients with pulmonary hypertension due to left-sided heart disease, classified by the World Health Organization (WHO) as Group 2 Pulmonary Hypertension. As many as two-thirds of heart failure patients around the world have elevated pulmonary vascular resistance, which is shown to lead to an increased risk of mortality and hospitalization. There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients.
'We are thrilled with this positive feedback from FDA. The granting of Breakthrough Device Designation marks another important milestone for our pulmonary denervation clinical development program,' said Martin Grasse, Chief Executive Officer of Gradient. 'We remain focused on completion of our early feasibility study as a crucial first step toward developing a targeted treatment option with the potential to improve outcomes and quality of life for these underserved patients.'
About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use.
For more information, please visit: https://www.gradientdenervation.com.
CONTACT: Media Contact info@gradientdenervation.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
11 minutes ago
- The Hill
Blue states call on FDA to expand abortion pill access
Attorneys general of New York, California, New Jersey and Massachusetts are asking the Food and Drug Administration (FDA) to expand access to the abortion pill and remove some 'unnecessary' drug restrictions that have been in place for more than two decades. The joint petition, filed Thursday, comes days after FDA Commissioner Marty Makary committed to reviewing the abortion drug amid pressure from Department of Health and Human Services Secretary Robert F. Kennedy Jr. and some Republican lawmakers. The FDA first approved of the use of mifepristone and misoprostol for an abortion in 2000. Unlike surgical abortions, medication abortions do not need to take place in a clinical setting, and patients are able to take the pills at home. Most abortions in the U.S. are now medication abortions, according to data from the reproductive health and rights group Guttmacher Institute. In 2023, 63 percent of all abortions in the U.S. were medication abortions. The safety of mifepristone has come under increased scrutiny by some Republican lawmakers, citing a flawed study claiming the rate of adverse health events that occur among patients is far higher than previously reported. More than 100 scientific studies have been conducted looking at the safety and efficacy of mifepristone and misoprostol; all of them have found that the drugs are a safe way to terminate a pregnancy. 'Given Mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' Mifepristone's use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program under the FDA. The attorneys general argue three requirements under the REMS program for the drug should be removed since they pose a burden to patients and health care systems. The first is related to prescriber certification. As part of the REMS program, health care providers who prescribe mifepristone are required to add their names to national and abortion provider lists, which the attorneys general say raise 'serious safety and legal concerns.' The second has to do with patient agreement forms. All patients who want mifepristone — even those using the drug to treat a miscarriage — are required to sign a document stating they are using the drug to end a pregnancy. The third requirement mentioned in the petition is connected to pharmacy certification. As part of mifepristone's REMS program, pharmacies that carry the drug are subject to tracking, shipping and reporting requirements, which the attorneys general argue may 'dissuade' some from carrying the drug. The FDA has yet to reply to a request for comment from The Hill about the petition.
Bloomberg
27 minutes ago
- Bloomberg
Japan's Ispace Tries to Become First Non-US Firm to Land on Moon
Tokyo-based ispace Inc. is slated to try to land a craft on the moon in a few hours, attempting to become the first non-US company to reach the lunar surface intact after a 2023 failure. Ispace's Resilience lander is expected to touch down on the moon after 3 p.m. New York time on Thursday.
Newsweek
27 minutes ago
- Newsweek
Albertsons Food Recalled in 12 States as FDA Issues Most Severe Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Albertsons Companies has issued a voluntary recall of multiple store-prepared Greek salad products sold across 12 states and Washington, D.C. The U.S. Food and Drug Administration (FDA) has classified the alert as a Class I recall—its highest and most urgent warning level. The salads were made using cucumbers linked to a multistate salmonella outbreak traced back to Bedner Growers Company. Newsweek has contacted Albertsons, via email, and Bedner Growers Company, via online contact form, for comment. Why It Matters A Class I recall is reserved for products that pose a serious health risk with a "reasonable probability" of causing illness or even death if consumed. The recalled Greek salads were sold under several store brands in high-traffic northeastern grocery chains. The FDA warning elevates the urgency for consumers who may still have the product in their refrigerators, particularly those with compromised immune systems, children, and elderly individuals more vulnerable to foodborne illnesses. What to Know Recalled Products: AMCE Greek Salad AUTHENTIC FS Sold refrigerated in clear plastic containers by the pound UPC: 293070 ##### READY MEALS Greek Salad SS Sold refrigerated in clear plastic containers by the pound UPC: 292483 ##### Star Market Greek Salad FS Sold refrigerated in clear plastic containers by the pound UPC: 292329 ##### Reason for Recall: All three products contain cucumbers from Bedner Growers Company, which were previously recalled due to contamination with salmonella, a bacteria known to cause serious gastrointestinal illness. The outbreak has been under ongoing investigation by public health authorities. Where the Recall Applies: The salads were sold at stores in the following states: Connecticut Delaware Maine Massachusetts Maryland New Hampshire New Jersey New York Rhode Island Pennsylvania Vermont Virginia Washington, D.C. The affected salads were primarily sold in ACME, Star Market, and Ready Meals outlets. What People Are Saying Albertsons Companies stated in its press release that it is "committed to the highest standards of food safety" and that the recall was initiated "out of an abundance of caution." No illnesses have been officially linked to the salads yet, but the company has urged customers who purchased any of the listed products to discard them immediately or return them to the store for a full refund. The FDA emphasized the seriousness of the recall, pointing to the ongoing multistate salmonella outbreak and reiterating its warning that contaminated food—even if it looks or smells normal—can be dangerous. What's Next The full scope of the salmonella outbreak connected to the contaminated cucumbers is being investigated. Consumers are advised to check their refrigerators for any of the recalled Greek salad items and follow safety instructions. Albertsons said affected stores are posting notices and removing products from shelves. Additional recalls may be issued if more prepared foods containing the same contaminated cucumbers are identified.
